Posted by Michael Wonder on 20 Oct 2020
Health Canada has approved Taltz (ixekizumab) for the treatment of non-radiographic axial spondyloarthritis
19 October 2020 - Taltz is now approved to treat patients across the axSpA spectrum, including ankylosing spondylitis and non-radiographic axSpA.
On 14 October 2020, Health Canada approved Taltz for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have responded inadequately to, or are intolerant to conventional therapy.
Another first-in-class milestone for the treatment, this approval makes Taltz the first IL-17A inhibitor to be approved by Health Canada for nr-axSpA. This is the fourth indication for Taltz, which was first approved by Health Canada for moderate-to-severe plaque psoriasis in 2016, psoriatic arthritis in 2018, and ankylosing spondylitis in 2020.
